A key pathway involves the activation of the MEK-ERK axis, as demonstrated by Huang et al. in colorectal cancer, where HMGB1 released from chemotherapy-damaged cells triggers RAGE-dependent ERK1/2 activation, which in turn phosphorylates the mitochondrial fission protein Drp1 at Ser616. Here, MAPK3 is linked to colorectal cancer.